Skip to main content
. 2023 Mar 22;14:1024120. doi: 10.3389/fimmu.2023.1024120

Table 5.

The evidence quality of curcumin.

Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Primary outcomes
DAS28 The mean DAS28 in the intervention groups was
1.1 lower
(1.67 to 0.53 lower)
147
(7 studies)
⊕⊝⊝⊝
very low 1,2,3
ESR The mean ESR in the intervention groups was
54.67 lower
(88.32 to 21.02 lower)
191
(8 studies)
⊕⊝⊝⊝
very low 1,2,3,4
CRP The mean CRP in the intervention groups was
0.35 lower
(0.55 to 0.15 lower)
104
(5 studies)
⊕⊝⊝⊝
very low 1,2,3,4
RF The mean RF in the intervention groups was
51.3 lower
(60.59 to 42.01 lower)
60
(4 studies)
⊕⊝⊝⊝
very low 1,2,3,4

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI, Confidence interval;

GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1 Downgraded one level due to serious risk of bias (random sequence generation, allocation concealment, blinding, incomplete outcomes) and most of the data comes from the RCTs with moderate risk of bias.

2 Downgraded one level due to the probably substantial heterogeneity.

3 Downgraded one level due to the total sample size fails to meet the optimal information size.

4 Downgraded one level due to the publication bias.